CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jul 2024 19:29:44 By Nasdaq GlobeNewswire

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

18 Jun 2024 16:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2024 18:35:30 By Nasdaq GlobeNewswire

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

03 Jun 2024 12:00:00 By Nasdaq GlobeNewswire

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

03 Jun 2024 12:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

30 May 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

22 May 2024 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 May 2024 17:38:21 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

08 May 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

02 May 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

19 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

12 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

28 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

28 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

14 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jan 2024 16:33:42 By Nasdaq GlobeNewswire